Organogenesis (ORGO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
The 2026 annual meeting will be held virtually on June 15, 2026, with voting on director elections, executive compensation, and auditor ratification.
Stockholders of record as of April 23, 2026, are eligible to vote, with both Common and Convertible Preferred Stock voting as a single class on an as-converted basis.
The board recommends voting for all director nominees, approval of executive compensation, and ratification of RSM US LLP as auditor.
Voting matters and shareholder proposals
Proposals include re-election of nine directors, advisory approval of executive compensation, and ratification of RSM US LLP as independent auditor for 2026.
Stockholders may submit proposals for the 2027 annual meeting by December 31, 2026, for inclusion in the proxy statement.
Proxy voting is available online, by phone, or by mail, and stockholders can participate and vote during the virtual meeting.
Board of directors and corporate governance
The board consists of ten members, including one Preferred Director elected by holders of Convertible Preferred Stock, and a Lead Independent Director.
Board committees include Audit, Compensation, Nominating, and Research & Development, each with defined charters and independent membership.
Directors are compensated with annual retainers, committee fees, and equity awards, with changes to compensation effective April 1, 2026.
The board has adopted a code of ethics and corporate governance guidelines, and maintains policies for director nominations and stockholder communications.
Latest events from Organogenesis
- Q2 2026 revenue fell 58% and net loss widened to $96.3M amid ongoing market and regulatory disruption.ORGO
Q2 2026 - All directors re-elected, executive pay approved, and auditor ratified with no shareholder questions.ORGO
AGM 2026 - Q1 2026 revenue fell 58% and net loss widened amid CMS-driven disruption and restructuring.ORGO
Q1 2026 - Record 2025 results, but 2026 revenue expected to decline amid CMS-driven disruption before recovery.ORGO
Q4 2025 - Regulatory changes, new launches, and a robust pipeline position the company for strong future growth.ORGO
Cantor Global Healthcare Conference 2025 - Strong product innovation and regulatory adaptation drive growth amid reimbursement shifts.ORGO
2024 Cantor Fitzgerald Global Healthcare Conference - Q3 net income rose to $12.3M on 6% revenue growth; 2024 outlook strong despite regulatory risks.ORGO
Q3 2024 - Q2 revenue up 11% to $130.2M, but net loss widened on impairments and write-downs.ORGO
Q2 2024 - Q1 revenue dropped 21% and losses widened, but full-year guidance was reaffirmed.ORGO
Q1 2025